Skip to content
Tech News
← Back to articles

Isomorphic Labs raises $5 billion Series C for AI drug discovery

read original more articles
GoKawiil Brief

Isomorphic Labs, the AI-driven drug discovery company led by Demis Hassabis, announced a $5 billion Series C funding round co-led by Greenoaks, Sequoia Capital and Andreessen Horowitz, with Alphabet also participating. The round comes months after Hassabis stepped back from his role as CEO of Google DeepMind, and follows the startup's $2.1 billion Series B raised in May.

Why It Matters

GoKawiil's interpretation of the reporting above, not reported fact.

The massive raise reflects a broader surge of investor capital into AI-powered drug discovery, with Dealroom reporting $23.2 billion poured into the sector in 2026 alone, as rivals like OpenAI and Anthropic also push into biology-focused AI tools. Hassabis's continued leadership of Isomorphic despite leaving DeepMind suggests the drug discovery venture may now be central to his ambitions, positioning the company to compete for a leading role in AI-designed medicines heading toward clinical trials.

Key Takeaways

Source: cnbc.com — Kai Nicol-Schwarz, 2026-11-17

Published there as: “Demis Hassabis’ AI company raises $5 billion, months after he left as Google DeepMind CEO”

Read the original report → The summary and analysis above are GoKawiil's own, written from reporting by the source above. Facts and quotes belong to the original publisher.
Keep reading
google deepmind 59 briefs → demis hassabis 11 briefs → series c funding 11 briefs → ai drug discovery 4 briefs →